Literature DB >> 3407379

Platelet hyper- and hypoaggregability in different microangiopathic complications of diabetes mellitus.

P Szénási1, L Tóth, L Romics, L Kammerer.   

Abstract

In vitro platelet aggregometry was performed in 201 patients with diabetes mellitus, and in 106 controls. The complication-free and retinopathic patients showed hyperaggregability to collagen and arachidonic acid, and also to epinephrine and adenosine diphosphate when neuropathy occurred. Patients with nephropathy, both with and without azotemia, had diminished in vitro platelet responses to each of the four stimuli as compared to age- and sex-matched controls. These characteristics were independent of the type of diabetes. It is concluded that diabetic nephropathy is characterized by reduced platelet in vitro reactivity. Further research is necessary to explain in vitro hypoaggregability in contrast to the numerous proofs of in vivo hyperfunction of platelets in diabetes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3407379     DOI: 10.1007/bf02581240

Source DB:  PubMed          Journal:  Acta Diabetol Lat        ISSN: 0001-5563


  19 in total

1.  In vitro synthesis of hemoglobin AIc.

Authors:  R Flückiger; K H Winterhalter
Journal:  FEBS Lett       Date:  1976-12-01       Impact factor: 4.124

2.  Determination of blood glucose using 4-amino phenazone as oxygen acceptor.

Authors:  P Trinder
Journal:  J Clin Pathol       Date:  1969-03       Impact factor: 3.411

Review 3.  Do platelets have anything to do with diabetic microvascular disease?

Authors:  J A Colwell; P D Winocour; P V Halushka
Journal:  Diabetes       Date:  1983-05       Impact factor: 9.461

4.  Increased production of platelet thromboxane B2 in non-insulin-dependent diabetes. Relationship to vascular complications.

Authors:  A D'Angelo; P Micossi; P M Mannucci; B Garimberti; F Franchi; G Pozza
Journal:  Eur J Clin Invest       Date:  1984-04       Impact factor: 4.686

5.  Detection of early retinal changes in diabetes by vitreous fluorophotometry.

Authors:  J G Cunha-Vaz; J R Fonseca; J F Abreu; M A Ruas
Journal:  Diabetes       Date:  1979-01       Impact factor: 9.461

6.  Platelet thromboxane synthesizing activity in non-insulin-dependent diabetes: correlation with diabetic retinopathy and diabetic treatment.

Authors:  R Takahashi; M Shiraki; I Morita; H Ito; S Murota; H Orimo
Journal:  Prostaglandins Leukot Med       Date:  1985-02

7.  Platelet aggregation, beta-thromboglobulin and platelet factor 4 in diabetes mellitus and in patients with vasculopathy.

Authors:  J Fritschi; M Christe; B Lämmle; G A Marbet; W Berger; F Duckert
Journal:  Thromb Haemost       Date:  1984-12-29       Impact factor: 5.249

8.  PARD: platelet aggregation as a risk factor in diabetics: results of a prospective study.

Authors:  H K Breddin; H J Krzywanek; P Althoff; K Schöffling; K Uberla
Journal:  Horm Metab Res Suppl       Date:  1985

9.  Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis.

Authors:  G Di Minno; J Martinez; M L McKean; J De La Rosa; J F Burke; S Murphy
Journal:  Am J Med       Date:  1985-11       Impact factor: 4.965

10.  Epidemiological characteristics of platelet aggregability.

Authors:  T W Meade; M V Vickers; S G Thompson; Y Stirling; A P Haines; G J Miller
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.